Physician profile
Samala Swamy
NPI 1447227509
$2,706.34
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $902 · 2020: $781 · 2021: $617 · 2022: $406.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $710.60 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $402.56 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $319.45 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $311.26 | 2019-2021 | |
| Amgen INC. | $210.97 | 2019-2021 | |
| Irhythm Technologies, INC. | $108.54 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $63.96 | 2019-2020 | |
| Pfizer INC. | $63.01 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $34.25 | 2019 | |
| Abiomed | $25.79 | 2021 | |
| Esperion Therapeutics, INC. | $22.50 | 2020 | |
| Vifor Pharma, INC. | $22.39 | 2021 | |
| Astellas Pharma US INC | $20.46 | 2020 | |
| Edwards Lifesciences Corporation | $16.54 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $13.63 | 2021 | |
| Cardinal Health 200 LLC | $12.48 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.19 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samala Swamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.